Last updated: February 15, 2026
What is AVP-786 and its Development Status?
AVP-786, also known as BRX-830, is a proprietary combination of dextromethorphan and quinidine developed by Avanir Pharmaceuticals. It aims to treat neuropsychiatric conditions such as agitation associated with Alzheimer’s disease and other neuropsychiatric disorders. The drug leverages dextromethorphan’s NMDA receptor antagonism and sigma-1 receptor activity, with quinidine used to inhibit dextromethorphan metabolism, increasing its bioavailability.
As of 2023, AVP-786 has completed Phase 3 clinical trials for agitation in Alzheimer’s disease:
- Phase 3 Status: Data from the ENLIGHTEN-2 trial, involving over 400 patients, demonstrated statistically significant reduction in agitation symptoms measured by the Cohen-Mansfield Agitation Inventory (CMAI).
- Regulatory Path: Avanir submitted a New Drug Application (NDA) to the FDA in late 2022. The FDA’s review is ongoing, with a projected decision date set for mid-2023.
- Other Indications: Investigations continue into use for neuropathic pain, post-traumatic stress disorder (PTSD), and other neuropsychiatric conditions. These efforts are exploratory, with early-phase trials underway or planned.
How is AVP-786 Positioned in the Market?
Market positioning depends on efficacy, safety, and existing treatments:
| Attribute |
AVP-786 |
Competitors |
| Therapeutic focus |
Agitation in Alzheimer’s disease |
Risks of off-label use, limited options |
| Regulatory status |
NDA submitted, under review |
Few approved drugs for agitation; off-label treatments include risperidone and quetiapine |
| Safety profile |
Well-tolerated in trials, fewer extrapyramidal symptoms |
Antipsychotics carry risk of mortality, metabolic syndrome |
| Delivery mode |
Oral (tablet) |
Oral, injectable, or patch options |
The market launch of AVP-786 could offer an alternative to antipsychotics, which have significant safety concerns in elderly populations.
What is the Market Potential of AVP-786?
The Alzheimer's-related agitation market is projected to grow significantly:
- Market Size: Valued at approximately $2.1 billion in 2022; expected to reach $3.2 billion by 2030 at a CAGR of 5.4% (source [1]).
- Addressable Patients: Estimated 6 million Alzheimer's patients in the U.S., with approximately 80% experiencing agitation symptoms (source [2]). About 4.8 million patients could be candidates for AVP-786 upon approval.
- Pricing strategy: Estimated at $8,000–$12,000 annually per patient, considering market standards for neuropsychiatric drugs and cost savings over hospitalizations and caregiver burden.
The unmet need for safer, effective treatments positions AVP-786 favorably, potentially capturing a significant share of the agitation market if regulatory approval is granted.
What are the Risks and Challenges?
- Regulatory Review: The FDA’s decision hinges on the robustness of trial data; delays or requests for additional data could impact timing and market entry.
- Market Adoption: Prescriber hesitation due to safety concerns with existing therapies or skepticism about new drugs.
- Pricing and Reimbursement: Payers may demand robust cost-effectiveness data before coverage decisions.
- Competitive Landscape: Pending advancements from other biotech firms or generics in neuropsychiatric therapy could influence market penetration.
What are the Next Steps for AVP-786?
- FDA Decision: Anticipated mid-2023; a positive outcome could lead to a market launch within 6–12 months.
- Post-approval activities: Launch preparation, healthcare provider education, payer negotiations.
- Additional trials: For new indications or combination therapies to expand pre-commercial portfolio.
Key Takeaways
- AVP-786 has shown promising Phase 3 results for agitation in Alzheimer’s, with NDA submission completed.
- Market size for agitation in Alzheimer's and comparable neuropsychiatric disorders presents a growth opportunity.
- The drug’s safety profile and potential to reduce reliance on antipsychotics could differentiate it.
- Regulatory and market penetration risks remain; success hinges on final trial data and timely approval.
- Strategic focus on niche treatment of agitation in dementia could establish AVP-786 as a standard of care.
FAQs
1. When could AVP-786 reach the market?
Regulatory approval is expected in mid-2023, with commercialization possible within 6–12 months post-approval.
2. How does AVP-786 compare with existing treatments?
It offers a potentially safer profile than off-label antipsychotics, targeting agitation directly with fewer severe adverse effects.
3. What are the primary regulatory hurdles?
Demonstrating sufficient efficacy, safety, and benefit-risk profile to meet FDA standards, especially given the elderly target population's sensitivity.
4. What other indications are being explored for AVP-786?
Early-phase trials are assessing its efficacy in neuropathic pain and PTSD, but these are not yet commercially substantiated.
5. How might payer policies influence AVP-786’s uptake?
Cost-effectiveness evidence and safety profile could support broader reimbursement, especially if it reduces hospitalization costs and caregiver burden.
References
[1] MarketWatch, "Neuropsychiatric disorder therapeutics market size," 2022.
[2] Alzheimer's Association, Data and Statistics on Alzheimer's Disease, 2022.
